RCEL

Avita Medical Ltd

RCEL, USA

AVITA Medical, Inc., together with its subsidiaries, operates as a therapeutic acute wound care company in the United States, Japan, the European Union, Australia, and the United Kingdom. The company's lead product is the RECELL System, a cell harvesting device used for the treatment of thermal burn wounds and full-thickness skin defects, as well as for repigmentation of stable depigmented vitiligo lesions. It also provides RECALL autologous cell harvesting device, which can treat areas of up to 1,920 cm2; RECELL autologous cell harvesting device with ease-of-use, an enhanced ease-of-use device that can treat areas of up to 1,920 cm²; and RECELL GO mini autologous cell harvesting device, a line extension of the RECELL GO system to treat smaller wounds up to 480 cm2, as well as RECELL GO autologous cell harvesting device consisting of RECELL GO processing device, which controls and manages the pressure applied to disaggregate the donor skin cells and controls the incubation time of the RECELL Enzyme to optimize cell yield and promote cell viability; and RECELL GO preparation kit, which can treat areas up to 1,920 cm2. In addition, the company markets, sells, and distributes PermeaDerm, a biosynthetic wound matrix; and Cohealyx, a collagen-based dermal matrix. It serves hospitals, treatment centers, and distributors. The company was formerly known as AVITA Therapeutics, Inc. and changed its name to AVITA Medical, Inc. in December 2020. AVITA Medical, Inc. is headquartered in Valencia, California.

https://avitamedical.com

Stock Price

$ 0.00

0% increase compared to yesterday.

Dividend

Frequency:

N/A

Rate:

N/A

Next Payout:

N/A
RCEL
stock
RCEL

Avita Medical Inc. (NASDAQ:RCEL) Given Consensus Recommendation of "Hold" by Analysts MarketBeat

Read more →
RCEL
stock
RCEL

AVITA Medical (NASDAQ: RCEL) to present at Piper Sandler 37th Healthcare Conference Stock Titan

Read more →

Showing 2 of 10

Analyst Ratings & Sentiment

(Last Updated 2025-09-30)

Rating:

STRONG BUY

Target Price:

$8.0102

Analyst Picks

Strong Buy

3

Buy

0

Hold

1

Sell

0

Strong Sell

0

Sentiment:

Bullish

Finn Analysis

(Last Updated 2025-09-30)

Health Score

Price to Book Ratio (P/B)

-

Very Low

-16.15

Low ≤ 1

High ≥ 3

Return on Equity (ROE)

-

Very High

197.82 %

Low ≤ 5%

High ≥ 25%

Return on Assets (ROA)

-

Very Low

-20.69 %

Low ≤ 2%

High ≥ 10%

Free Cash Flow - Revenue % (FCF)

-

Very Low

-36.19 %

Low ≤ 5%

High ≥ 15%

Investors

* Institutions hold a combined 37.83% of the total shares of Avita Medical Ltd

1.

BlackRock Inc

(7.016%)

since

2025/06/30

2.

Vanguard Group Inc

(5.368%)

since

2025/06/30

3.

Vanguard Total Stock Mkt Idx Inv

(2.9944%)

since

2025/07/31

4.

iShares Russell 2000 ETF

(2.4016%)

since

2025/08/31

5.

Geode Capital Management, LLC

(2.2886%)

since

2025/06/30

6.

State Street Corp

(1.9571%)

since

2025/06/30

7.

UBS Group AG

(1.5167%)

since

2025/06/30

8.

Opaleye Management Inc

(1.4417%)

since

2025/06/30

9.

Millennium Management LLC

(1.3664%)

since

2025/06/30

10.

Vanguard Institutional Extnd Mkt Idx Tr

(0.9999%)

since

2025/07/31

11.

Fidelity Small Cap Index

(0.9757%)

since

2025/06/30

12.

Northern Trust Corp

(0.9608%)

since

2025/06/30

13.

iShares Russell 2000 Growth ETF

(0.8966%)

since

2025/08/31

14.

Morgan Stanley - Brokerage Accounts

(0.8224%)

since

2025/06/30

15.

Fidelity Extended Market Index

(0.5258%)

since

2025/07/31

16.

Jacobs Levy Equity Management, Inc.

(0.5115%)

since

2025/06/30

17.

Vanguard Russell 2000 ETF

(0.4724%)

since

2025/07/31

18.

Wellington Management Company LLP

(0.4097%)

since

2025/06/30

19.

State St Russell Sm Cap® Indx SL Cl I

(0.3509%)

since

2025/08/31

20.

Goldman Sachs Group Inc

(0.3466%)

since

2025/06/30

21.

Jane Street Group LLC

(0.321%)

since

2025/06/30

22.

Charles Schwab Investment Management Inc

(0.3176%)

since

2025/06/30

23.

Marshall Wace Asset Management Ltd

(0.2843%)

since

2025/06/30

24.

Schwab Small Cap Index

(0.2621%)

since

2025/07/31

25.

NT R2000 Index Fund - NL

(0.2337%)

since

2025/06/30

26.

Bank of America Corp

(0.2315%)

since

2025/06/30

27.

D. E. Shaw & Co LP

(0.2294%)

since

2025/06/30

28.

iShares Micro-Cap ETF

(0.224%)

since

2025/08/31

29.

Nuveen, LLC

(0.2195%)

since

2025/06/30

30.

Citadel Advisors Llc

(0.2175%)

since

2025/06/30

31.

Bank of New York Mellon Corp

(0.2045%)

since

2025/06/30

32.

Fidelity Total Market Index

(0.1863%)

since

2025/07/31

33.

NT R2000 Index Fund - DC - NL - 3

(0.1863%)

since

2025/06/30

34.

Extended Equity Market Fund K

(0.1828%)

since

2025/06/30

35.

Russell 2500â„¢ Index Fund F

(0.1804%)

since

2025/06/30

37.

iShares Core S&P Total US Stock Mkt ETF

(0.1521%)

since

2025/08/31

38.

Bridgeway Ultra-Small Company

(0.1392%)

since

2025/06/30

39.

Fidelity Series Total Market Index

(0.1382%)

since

2025/07/31

40.

SPDR® Russell 2000 US Small Cap ETF

(0.1338%)

since

2025/08/31

* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.

Earnings History

EPS ActualEPS EstimateEPS DifferenceSurprise Percent

Upcoming Earnings Release

Date

2025-12-31

EPS Estimate

-0.2617

Latest Release

Date

2025-09-30

EPS Actual

-0.7116

EPS Estimate

-0.41

EPS Difference

-0.3016

Surprise Percent

-73.561%

Investing Fit Scorecard

(Last Updated 2025-09-30)

Deep Value
Weak Deep Value(1.5)
Defensive
Highly Defensive(7)
Dividend
Weak Dividend Profile(1.5)
Economic Moat
Wide Moat Company(6.3)
GARP
Not Attractive for GARP(2.5)
Growth
Weak Growth Prospect(2.5)
Momentum
No Momentum(3)
Net Net
Not Undervalued (Net-Net)(0.5)
Quality
Low Quality Business(3)
Value
Fair Value(4.5)

Income Statement

(Last Updated 2025-09-30)

Revenue

$ 0

Cost Of Revenue

$ 0

Gross Profit

$ 0

Operating Expenses

$ 0

Operating Income

$ 0

Interest Expense

$ 0

Pretax Income

$ 0

Net Income

$ 0

Income Tax Expense

$ 0

EBITDA

$ 0

Total Other Income Expense Net

$ 0

Earnings Per Share

0

Dividends Per Share

0

Shares Outstanding

0

Operating Margin

0%

Trend

Balance Sheet

(Last Updated 2025-09-30)

Cash

$ 0

Short Term Investments

$ 0

Receivables

$ 0

Inventories

$ 0

Total Current Assets

$ 0

Property Plant Equipment

$ 0

Total Assets

$ 0

Payables

$ 0

Short Term Debt

$ 0

Long Term Debt

$ 0

Total Liabilities

$ 0

Equity

$ 0

Trend

Cash Flow

(Last Updated 2025-09-30)

Net Income

$ 0

Depreciation

$ 0

Change In Working Capital

$ 0

Cash From Operations

$ 0

Capital Expenditures

$ 0

Cash From Investing

$ 0

Cash From Financing

$ 0

Net Change In Cash

$ 0

Trend

Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.